SunBird Bio

Market position

The company describes itself as offering the broadest blood-based diagnostic panel for neurological disorders and claims first-of-its-kind capability for direct detection of EV-bound aggregated proteins in blood; these are company characterizations rather than independently verified positions. Comparators cited in the sources are PET imaging, CSF-based tests and other blood-based diagnostics.

The company attributes its differentiation to direct detection of EV-bound, aggregated disease proteins in blood using a proprietary sensor and optical amplification, and to a modular platform design that allows new biomarker assays to be added as they are discovered.

Technology

The platform uses a proprietary sensor design with optical amplification to directly detect and measure very low concentrations of extracellular-vesicle (EV)-bound, aggregated proteins in blood. According to the company, aggregated proteins such as tau bind to nanoscale brain-derived extracellular vesicles that cross the blood-brain barrier into the bloodstream at scarce levels that most blood tests cannot accurately detect. The design allows additional assays to be added as new protein biomarkers are identified, and is positioned as an alternative to PET imaging, cerebrospinal fluid-based tests and other blood-based diagnostics.

Go-to-market

Partnership-led: the company states it is securing collaborations with biopharma companies and other organizations to accelerate development of the platform and conduct clinical studies, and presents clinical data at scientific conferences such as the Alzheimer's Association International Conference.

Researchers and clinicians involved in the diagnosis and monitoring of neurological disorders, and biopharma companies seeking diagnostics for patient enrollment, stratification, longitudinal monitoring and target engagement in drug development.

Geography

Jointly headquartered in Cambridge, Massachusetts (United States) and Singapore. Clinical sample collection for its tau study was conducted at four global sites.

History

A 2023 report states that Glympse Bio, a Cambridge, Massachusetts developer of an injectable diagnostic platform, was acquired by Sunbird Bio in August 2023, with plans to direct combined resources toward a blood test for Alzheimer's disease; another item from April 2023 describes the same transaction as US-based Glympse Bio acquiring Singapore-based Sunbird Bio. In July 2024 the company presented tau biomarker data at AAIC, and in October 2024 it closed a $14 million financing with new investors Eli Lilly and Company and EDBI alongside existing investors ClavystBio, Polaris Partners and S32.

Risks & controversies

Sources give conflicting accounts of the direction of the 2023 Glympse Bio transaction: one report states Sunbird Bio acquired Glympse Bio in August 2023, while another states Glympse Bio acquired Sunbird Bio in April 2023. The clinical evidence reported to date comes from a small study (10 tau-PET positive and 22 control participants), and the company said a larger validation study was still planned.